KLK2 and prostate carcinoma: The formation of an immune synapse via this bispecific antibody is intended to activate T cells by binding to CD3 and redirecting them to KLK2-positive prostate cancer cells, facilitating KLK2-specific T-cell activation and targeted tumor lysis.